

References

I-198

1. Insogna K, Rauch F, Kamenicky P, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: A phase 3, single —arm, international trial. *J Bone Miner Res.* 2019;34 (12): 2183-2191.
2. Day A, Gutierrez OM, Guthrie BL, et al. Burosumab in tumor-induced osteomalacia: A case report. *Joint bone spine.* 2020;87(1):81-83
3. Briot K, Portale A, Brandi M, et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. *RMD Open.* 2021;7(3):e001714.
4. Burosumab-twza. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 17, 2019.
5. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. . Burosumab.
6. Micromedex DrugDex Compendium®. 2022. Burosumab (Crysvita)
7. Crysvita (burosumab-twza), injection, for subcutaneous use [package insert]. Ultragenyx Pharmaceutical, Inc. Novato, Ca. Revised 06/2020.